Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 8, 2012, Pages 837-858

  Torres, Dawn M ^a   Williams, Christopher D ^b   Harrison, Stephen A ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

Cancer Risk; Diagnosis; Epidemiology; Mechanisms

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; BETAINE; CARBAMAZEPINE; EXENDIN 4; EZETIMIBE; FRUCTOSE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LIRAGLUTIDE; LOSARTAN; LOW DENSITY LIPOPROTEIN; METFORMIN; NIVOCASAN; OBETICHOLIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TELMISARTAN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ABDOMINAL OBESITY; BARIATRIC SURGERY; CLINICAL FEATURE; COFFEE; COMPUTER ASSISTED TOMOGRAPHY; DECOMPENSATED LIVER CIRRHOSIS; DIET THERAPY; DISEASE ASSOCIATION; ECHOGRAPHY; ELASTOGRAPHY; EXERCISE; GLUCOSE BLOOD LEVEL; HIGH FRUCTOSE CORN SYRUP; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORTALITY; NAUSEA; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; ROUX Y ANASTOMOSIS; SIDE EFFECT; SLEEVE GASTRECTOMY; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DIET; FATTY LIVER; HEPATIC INSUFFICIENCY; HUMANS; LIVER NEOPLASMS; MOTOR ACTIVITY; RADIOGRAPHY, ABDOMINAL; UNITED STATES;

EID: 84864081494     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.03.011     Document Type: Review

References (261)

1. Liangpunsakul S., Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol 2003, 37:340-343.
2. Baranova A., Tran T.P., Birerdinc A., et al. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011, 33:801-814.
3. Lee Y.I., Lim Y.S., Park H.S. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol 2012, 27:91-95.
4. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
5. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
6. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42:641-649.
7. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
8. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
9. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
10. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
11. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
12. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
13. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
14. Bambha K., Belt P., Abraham M., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55:769-780.
15. Lomonaco R., Ortiz-Lopez C., Orsak B., et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology 2011, 54:837-845.
16. Fan J.G., Farrell G.C. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50:204-210.
17. Hashimoto E., Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011, 46:63-69.
18. Caballería L., Pera G., Auladell M.A., et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010, 21:24-32.
19. Ruhl C.E., Everhart J.E. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004, 8:501-519.
20. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in type 2 diabetic patients. Diabetes Care 2007, 30:1212-1218.
21. Younossi Z.M., Gramlich T., Matteoni C.A., et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004, 2:262-265.
22. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010, 105:1567-1573.
23. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303:242-249.
24. Schwimmer J.B., Deutsch R., Kahen T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
25. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538-1544.
26. Harrison S.A., Oliver D., Arnold H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447.
27. Fracanzani A.L., Valenti L., Bugianesi E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48:792-798.
28. Tahan V., Canbakan B., Balci H., et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008, 55:1433-1438.
29. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485.
30. Haring R., Wallaschofski H., Nauck M., et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
31. Francque S., De Maeght S., Adler M., et al. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT: results of the Belgian NAFLD registry. Acta Gastroenterol Belg 2011, 74:9-16.
32. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1416-1419.
33. Dam-Larsen S., Becker U., Franzmann M.G., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44:1236-1243.
34. Söderberg C., Stål P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up period. Hepatology 2010, 51:595-602.
35. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver disease: a follow-up study. Hepatology 1995, 22:1714-1719.
36. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
37. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
38. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Hepatology 2005, 42:132-138.
39. Zein C.O., Unalp A., Colvin R., et al. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011, 54:753-759.
40. Angulo P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology 2011, 53:1792-1794.
41. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
42. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
43. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38:420-427.
44. Yatsuji S., Hashimoto E. Natural history of Japanese patients with non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis (NASH) patients with hepatocellular carcinoma (HCC). Nihon Rinsho 2006, 64:1173-1179.
45. Yatsuji S., Hashimoto E., Tobari M., et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009, 24:248-254.
46. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence risk factors for hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
47. O'Leary J.G., Landaverde C., Jennings L., et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011, 9:700-704.
48. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weightly connection. Hepatology 2010, 51:1820-1832.
49. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433.
50. Kawada N., Imanaka K., Kawaguchi T., et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009, 44:1190-1194.
51. Hashizume H., Sato K., Takagi H., et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007, 19:827-834.
52. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
53. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996, 62:1246-1251.
54. Angele M.K., Rentsch M., Hartl W.H., et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 2008, 195:214-220.
55. Spitzer A.L., Lao O.B., Dick A.A., et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010, 16:874-884.
56. Charlton M.R., Burns J.M., Pederson R.A., et al. Frequency and outcomes of liver transplantations for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
57. Barritt A.S., Dellon E.S., Kozlowski T., et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol 2011, 45:372-378.
58. Malik S.M., deVera M.E., Fontes P., et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009, 9:782-793.
59. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001, 7:363-373.
60. Yalamanchili K., Saadeh S., Klintmalm G.B., et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010, 16:431-439.
61. Treeprasertsuk S., Lopez-Jimenez F., Lindor K.D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011, 56:35-45.
62. Caserta C.A., Pendino G.M., Amante A., et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol 2010, 171:1195-1202.
63. Musso G. The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk. Ann Med 2011, 43:413-417.
64. Fan J.G., Li F., Cai X.B., et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
65. Adams L.A., Waters O.R., Knuiman M.W., et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009, 104:861-867.
66. Ortiz-Lopez C., Lomonaco R., Orsak B., et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012, 35:873-878.
67. Singh H., Pollock R., Uhanova J., et al. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005, 50:2338-2343.
68. Daltro C., Cotrim H.P., Alves E., et al. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: just a coincidence?. Obes Surg 2010, 20:1536-1543.
69. Chin K., Nakamura T., Takahashi K., et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med 2003, 114:370-376.
70. Burke C.A. Colonic complications of obesity. Gastroenterol Clin North Am 2010, 39:47-55.
71. Hwang S.T., Cho Y.K., Park J.H., et al. Relationship of nonalcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010, 25:562-567.
72. Wong V.W., Wong G.L., Tsang S.W., et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011, 60:829-836.
73. Touzin N.T., Bush K.N., Williams C.D., et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2011, 4:169-176.
74. Li Y., Xu C., Yu C., et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009, 50:1029-1034.
75. Petta S., Cammà C., Cabibi D., et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011, 34:757-766.
76. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
77. Lim L.Y., Chalasani N. Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep 2012, 14:67-73.
78. Barchetta I., Angelico F., Del Ben M., et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011, 9:85.
79. Targher G., Bertolini L., Scala L., et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007, 17:517-524.
80. Liangpunsakul S., Chalasani N. Serum vit D concentrations and unexplained elevation in ALT among US adults. Dig Dis 2011, 56:2124-2129.
81. Nseir W., Taha H., Khateeb J., et al. Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig Dis Sci 2011, 56:3328-3334.
82. Putz-Bankuti C., Pilz S., Stojakovic T., et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int 2012, 32:845-851.
83. Roth C.L., Elfers C.T., Figlewicz D.P., et al. Vitamin D deficiency in obese rats exacerbates NAFLD and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012, 55:1103-1111.
84. Nakano T., Cheng Y.F., Lai C.Y., et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011, 55:415-425.
85. Kowdley K.V., Belt P., Wilson L.A., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85.
86. Fracanzani A.L., Valenti L., Bugianesi E., et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol 2011, 54:1244-1249.
87. Manousou P., Kalambokis G., Grillo F., et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011, 31:730-739.
88. van Geenen E.J., Smits M.M., Schreuder T.C., et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010, 39:1185-1190.
89. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
90. Cusi K. Role of insulin resistance in lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009, 13:544-563.
91. Kanuri G., Spruss A., Wagnerberger S., et al. Role of tumor necrosis factor α in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011, 22:527-534.
92. Lomonaco R., Ortiz-Lopez C., Orsak B., et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with NAFLD. Hepatology 2012, 55:389-397.
93. Kumashiro N., Erion D.M., Zhang D., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011, 108:16381-16385.
94. Fuchs M. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid X receptor as an emerging treatment target. J Lipids 2012, 2012:934396.
95. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology 2011, 53:1023-1034.
96. Inagaki T., Moschetta A., Lee Y.K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103:3920-3925.
97. Watanabe M., Houten S.M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
98. Jansen P.L. A new life for bile acids. J Hepatol 2010, 52:937-938.
99. Keitel V., Donner M., Winandy S., et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008, 372:78-84.
100. Anstee Q.M., Day C.P. A lipid to treat non-alcoholic fatty liver disease: the dawn of lipo-rehabilitation. J Hepatol 2012, 56:987-989.
101. Lee J.M., Lee Y.K., Mamrosh J.L., et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 2011, 474:506-510.
102. Watanabe M., Houten S.M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004, 113:1408-1418.
103. Poupeau A., Postic C. Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors. Biochim Biophys Acta 2011, 1812:995-1006.
104. Fontaine C., Rigamonti E., Nohara A., et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007, 101:40-49.
105. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
106. Speliotes E.K., Butler J.L., Palmer C.D., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
107. Valenti L., Alisi A., Galmozzi E., et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
108. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883-1894.
109. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362:1082-1089.
110. Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011, 54:1650-1660.
111. Valenti L., Nobili V., Al-Serri A., et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver disease. J Hepatol 2011, 55:1409-1414.
112. Petit J.M., Guiu B., Masson D., et al. Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes. Hepatology 2011, 54:1109-1110.
113. Kozlitina J., Boerwinkle E., Cohen J.C., et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
114. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identified variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.
115. Santoro N., Zhang C.K., Zhao H., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012, 55:781-789.
116. Jung Y., Witek R.P., Syn W.K., et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 2010, 59:655-665.
117. Nitta T., Kim J.S., Mohuczy D., et al. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008, 48:909-919.
118. Philips G.M., Chan I.S., Swiderska M., et al. Hedgehog signaling pathway antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One 2011, 6:e23943.
119. Choi S.S., Omenetti A., Witek R.P., et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1093-G1106.
120. Choi S.S., Omenetti A., Syn W.K., et al. The role of hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol 2011, 43:238-244.
121. Syn W.K., Jung Y., Omenetti A., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137:1478-1488.
122. Amir M., Czaja M.J. Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011, 5:159-166.
123. Mei S., Ni H.M., Manley S., et al. Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. J Pharmacol Exp Ther 2011, 339:487-498.
124. Thoen L.F., Guimarães E.L., Dollé L., et al. A role for autophagy during hepatic stellate cell activation. J Hepatol 2011, 55:1353-1360.
125. Puri P., Mirshahi F., Cheung O., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
126. Wang Y., Ausman L.M., Russell R.M., et al. Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr 2008, 138:1866-1871.
127. Ibrahim S.H., Gores G.J. Who pulls the trigger: JNK activation in liver lipotoxicity?. J Hepatol 2012, 56:17-19.
128. Fuest M., Willim K., Macnelly S., et al. The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. Hepatology 2012, 55:408-418.
129. Rangwala F., Guy C.D., Lu L., et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 2011, 224:401-410.
130. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:691-701.
131. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
132. Vanderhoof J.A., Tuma D.J., Antonson D.L., et al. Effect of antibiotics in the prevention of jejunoileal bypass-induced liver dysfunction. Digestion 1982, 23:9-15.
133. Drenick E.J., Fisler J., Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82:535-548.
134. Hamaguchi M., Kojima T., Itoh Y., et al. The severity of ultrasound findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102:1-8.
135. Charatcharoenwitthaya P., Lindor K.D. Role of radiologic modalities in the management of nonalcoholic steatohepatitis. Clin Liver Dis 2007, 11:37-54.
136. Schwenzer N.F., Springer F., Schraml C., et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433-445.
137. Hernaez R., Lazo M., Bonekamp S., et al. Diagnosis accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011, 54:1082-1090.
138. West J., Card T.R. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010, 139:1230-1237.
139. Yoneda M., Mawatari H., Fujita K., et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:371-378.
140. Nobili V., Vizzutti F., Arena U., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48:442-448.
141. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
142. Myers R.P., Elkashab M., Ma M., et al. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol 2010, 24:661-670.
143. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
144. Myers R.P., Pomier-Layrargues G., Kirsch R., et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatology 2012, 56:564-570.
145. Myers R.P., Pomier-Layrargues G., Kirsch R., et al. Feasibility and diagnostic performance of the Fibroscan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012, 55:199-208.
146. De Ledinghen V., Wong V.W., Vergniol J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan. J Hepatol 2012, 56:833-839.
147. Yoneda M., Suzuki K., Kato S., et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010, 256:640-647.
148. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
149. Yin M., Talwalkar J.A., Glaser K.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1213.
150. Chen J., Talwalkar J.A., Yin M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011, 259:749-756.
151. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
152. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
153. Tamimi T.I., Elgouhari H.M., Alkhouri N., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229.
154. Joka D., Wahl K., Moeller S., et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012, 55:455-464.
155. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
156. Younossi Z.M., Jarrar M., Nugent C., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-1437.
157. Castera L. Noninvasive diagnosis of steatosis and fibrosis. Diabetes Metab 2008, 34:674-679.
158. McPherson S., Stewart S.F., Henderson E., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59:1265-1269.
159. Calès P., Boursier J., Chaigneau J., et al. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 2010, 30:1346-1354.
160. Raszeja-Wyszormirska J., Szymanik B., Ławniczak M., et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010, 28:67.
161. Fujii H., Enomoto M., Fukushima W., et al. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009, 58:1566-1567.
162. Ruffillo G., Fassio E., Alvarez E., et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011, 54:160-163.
163. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic steatohepatitis clinical research network: design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1312-1321.
164. Satapathy S.K., Sanyal A.J. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010, 21:668-675.
165. Kirk E., Reeds D.N., Finck B.N., et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009, 136:1552-1560.
166. Lazo M., Solga S.F., Horska A., et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010, 33:2156-2163.
167. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized control trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 2010, 51:121-129.
168. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100:1072-1081.
169. Suzuki A., Lindor K., St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43:1060-1066.
170. Baba C.S., Alexander G., Kalyani B., et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 21:191-198.
171. Oza N., Eguchi Y., Mizuta T., et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009, 44:1203-1208.
172. Kistler K.D., Brunt E.M., Clark J.M., et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011, 106:460-468.
173. Krasnoff J.B., Painter P.L., Wallace J.P., et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008, 47:1158-1166.
174. St George A., Bauman A., Johnston A., et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50:68-76.
175. Perseghin G., Lattuada G., De Cobelli F., et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007, 30:683-688.
176. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008, 48:1791-1798.
177. Johnson N.A., Sachinwalla T., Walton D.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50:1105-1112.
178. Sullivan S., Kirk E.P., Mittendorfer B., et al. Randomized trial of exercise effect of intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012, 55:1738-1745.
179. Ismail I., Keating S.E., Baker M.K., et al. A systematic review and meta-analysis of the effect of aerobic vs resistance exercise training on visceral fat. Obes Rev 2012, 13:68-91.
180. Hallsworth K., Fattakhova G., Hollingsworth K.G., et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut 2011, 60:1278-1283.
181. Zivkovic A.M., German J.B., Sanyal A.J. Comparative review of diets for the metabolic syndrome: implications for non-alcoholic fatty liver disease. Am J Clin Nutr 2007, 86:285-300.
182. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
183. Tetri L.H., Basaranoglu M., Brunt E.M., et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295:G987-G995.
184. Samuel V.T. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab 2011, 22:60-65.
185. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
186. Kohli R., Kirby M., Xanthakos S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934-945.
187. Cortez-Pinto H., Jesus L., Barros H., et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients?. Clin Nutr 2006, 25:816-823.
188. Toshimitsu K., Matsuura B., Ohkubo I., et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007, 23:46-52.
189. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 56:944-951.
190. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32:365-372.
191. Klatsky A.L., Armstrong M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992, 136:1248-1257.
192. Freedman N.D., Everhart J.E., Lindsay K.L., et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50:1360-1369.
193. Modi A.A., Feld J.J., Park Y., et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010, 51:201-209.
194. Molloy J.W., Calcagno C.J., Williams C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis and degree of hepatic fibrosis. Hepatology 2012, 55:429-436.
195. Liu X., Lazenby A.J., Clements R.H., et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007, 17:486-492.
196. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis, effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368-373.
197. Csendes A., Smok G., Burgos A.M. Histological findings in the liver before and after gastric bypass. Obes Surg 2006, 16:607-611.
198. Chavez-Tapia N.C., Tellez-Avila F.I., Barrientos-Gutierrez T., et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, 1. CD007340.
199. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137:532-540.
200. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396-1402.
201. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647-1654.
202. Ribeireiro T., Swain J., Sarr M., et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery: a prospective analysis. Obes Surg 2011, 21:310-315.
203. Dallal R.M., Mattar S.G., Lord J.L., et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 2004, 14:47-53.
204. Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo controlled trial of orlistat for treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
205. Harrison S.A., Brunt E.M., Fecht W.J., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology 2009, 49:80-86.
206. Scheen A.J. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007, 21:535-553.
207. Gary-Bobo M., Elachouri G., Gallas J.F., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007, 46:122-129.
208. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
209. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
210. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
211. Ratziu V., Charlotte F., Bernhardt C., et al. Long term efficacy of rosliglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
212. Boettcher E., Csako G., Pucino F., et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012, 35:66-75.
213. Lutchman G., Modi A., Kleiner D.E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007, 46:424-429.
214. Murphy C.E., Rodgers P.T. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007, 41:2014-2018.
215. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
216. Singh S., Loke Y., Furberg C. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 98:1189-1195.
217. Lin H.Z., Yang S.Q., Chuckaree C., et al. Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat Med 2000, 6:998-1003.
218. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
219. Haukeland J.W., Konopski Z., Eggesbø H.B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
220. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
221. Torres D.M., Jones F.J., Shaw J.C., et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 2011, 54:1631-1639.
222. Mehta K., Van Thiel D.H., Shah N., et al. Nonalcoholic fatty liver disease: pathogenesis and the role of anti-oxidants. Nutr Rev 2002, 60:289-293.
223. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-2490.
224. Sanyal A.J., Mofrad P.S., Contos M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107-1115.
225. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high dose vitamin E supplementation may increase all cause mortality. Ann Intern Med 2005, 142:37-46.
226. Song Z., Deaciuc I., Zhou Z., et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G894-G902.
227. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic steatohepatitis: results of a randomized placebo-controlled trial. Hepatology 2009, 50:1818-1826.
228. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
229. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomised placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
230. Adams L.A., Angulo P., Petz J., et al. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010, 4:628-633.
231. Leuschner U.F., Lindenthal B., Herrmann G., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52:472-479.
232. Ratziu V., de Ledinghen V., Oberti F., et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011, 54:1011-1019.
233. Koppe S.W., Sahai A., Malladi P., et al. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004, 41:592-598.
234. Preaux A.M., Mallat A., Rosenbaum J., et al. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997, 26:1047-1054.
235. Adams L.A., Zein C.O., Angulo P., et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368.
236. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis, and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 22:634-638.
237. Van Wagner L.B., Koppe S.W., Brunt E.M., et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011, 10:277-286.
238. Zein C.O., Yerian L.M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54:1610-1619.
239. Gómez-Domínguez E., Gisbert J.P., Moreno-Monteagudo J.A., et al. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
240. Hyogo H., Ikegami T., Tokushige K., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2011, 41:1057-1065.
241. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St. Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106:71-77.
242. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver function tests in the GREACE study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
243. Nozaki Y., Fujita K., Yoneda M., et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009, 51:548-556.
244. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:101-107.
245. Hirose A., Ono M., Saibara T., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.
246. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331-1336.
247. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
248. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes mellitus. JAMA 2007, 298:194-206.
249. Gupta N.A., Mells J., Dunham R.M., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51:1584-1592.
250. Sharma S., Mells J.E., Fu P.P., et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautopathy. PLoS One 2011, 6:e25269.
251. Ding X., Saxena N.K., Lin S., et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
252. Tushuizen M.E., Bunck M.C., Pouwels P.J., et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015-1017.
253. Kenny P.R., Brady D.E., Torres D.M., et al. Exenatide in the treatment of diabetic patients with nonalcoholic fatty steatohepatitis: a case-series. Am J Gastroenterol 2010, 105:2707-2709.
254. Samson S.L., Sathyanarayana P., Jogi M., et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomized controlled trial. Diabetologia 2011, 54:3093-3100.
255. Blevins T., Pullman J., Malloy J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:1301-1310.
256. Lee J.W., Cho Y.K., Ryan M., et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010, 4:378-383.
257. Suzuki I., Yamauchi T., Onuma M., et al. Allopurinol, an inhibitor of uric acid synthesis: can it be used for the treatment of metabolic syndrome and related disorders?. Drugs Today 2009, 45:363-378.
258. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
259. Hidvegi T., Ewing M., Hale P., et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010, 329:229-232.
260. Sanyal A.J., Mudaliar S., Henry R.R., et al. A new therapy for nonalcoholic fatty liver disease and diabetes?. INT-747-the first FXR hepatic therapeutic study. Hepatology 2009, 50:389A.
261. Ratziu V., Sheikh M.Y., Sanyal A.J., et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012, 55:419-428.